Overview

The Study of Efficacy and Safety of Mexidol® in Stroke Therapy (MIR)

Status:
COMPLETED
Trial end date:
2023-08-18
Target enrollment:
Participant gender:
Summary
The main purpose of the clinical trial is to assess efficacy and safety of Mexidol® in sequential treatment (solution for intravenous and intramuscular administration 50 mg/ml + film-coated tablets 250 mg) of patients in the acute and early recovery periods of ischemic stroke.
Phase:
PHASE3
Details
Lead Sponsor:
Pharmasoft
Treatments:
emoxypine succinate
ethylmethylhydroxypyridine succinate